{'fraction_non_alphanumeric': 0.01627906976744186, 'fraction_numerical': 0.004651162790697674, 'mean_word_length': 5.630769230769231, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Safety concern clouds outcome of baclofen study for alcohol dependence

A 12‐week study has found that the selective gamma‐aminobutyric acid (GABA) receptor agonist baclofen improved drinking outcomes in patients with alcoholic liver disease. However, a high prevalence of serious adverse events among patients taking a higher dose of the study medication raises concerns about how widely used this treatment option should become.